PolyTherics Receives Second Patent Allowance in Record Time
News Jul 08, 2009
PolyTherics Limited (PolyTherics), the biopharmaceuticals company dedicated to precision engineering of biologics to improve their pharmacokinetic properties, has announced that a second patent has been allowed covering the targeted PEGylation of proteins.
Issued by the United States Patent Office, this allowance protects PolyTherics’ PEGylation technology in the two largest pharmaceutical markets in the world. This news comes just two weeks after the allowance of the first patent within Europe.
The patent claims the use of a unique linker developed at PolyTherics that enables precision attachment of PEG to natural disulfide bonds in proteins. Trademarked as TheraPEG™, the technology allows proteins with proven therapeutic efficacy such as Interferons, erythropoietin and antibody fragments to remain active and potent in the body for longer, resulting in less frequent dosing without loss of biological activity.
TheraPEG™ has been shown to be an efficient and reliable process which complements the cost benefits of bacterial expression to produce therapeutic proteins.
Keith Powell, CEO of PolyTherics commented: “Having received the allowance of our first patent less than two weeks ago, it is a real thrill to have this second notification from the US Patent Office so quickly. In the space of time that the Wimbledon tennis championships have taken place, we have been given patent coverage in the two largest pharmaceutical markets in the world. This is a huge achievement for us and underpins both the novelty of our third generation pegylation technology and the quality of the underlying patent submission. The TheraPEG™ technology is already being used by several of our partners to develop and eventually commercialize therapeutic proteins in PEGylated form”.
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019